Macrogenics (MGNX) Cash from Operations (2012 - 2026)
Macrogenics (MGNX) posted quarterly Cash from Operations of 35811000.0 for Q1 2026, up 23.63% year-over-year from 28966823.47 in Q1 2025, and down 183.24% quarter-over-quarter from 43021000.0 in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) Cash from Operations (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Cash from Operations for 15 consecutive years, with 35811000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 23.63% year-over-year to 35811000.0; the TTM figure through Mar 2026 stood at 69961000.0 (changed 0.49% YoY), while the FY2025 annual figure was 81040000.0, down 18.53% from the prior year.
- Cash from Operations slipped to 35811000.0 in Q1 2026 per MGNX's latest filing, from 43021000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 60162000.0 in Q3 2024 and bottomed at 57696000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 20611058.82 across 5 years, with a median of 35246000.0 in 2023.
- On a YoY basis, Cash from Operations climbed as much as 270.69% in 2024 and fell as far as 2029.49% in 2024.
- Macrogenics' Cash from Operations stood at 29320000.0 in 2022, then plunged by 195.62% to 28037000.0 in 2023, then tumbled by 36.99% to 38407000.0 in 2024, then surged by 212.01% to 43021000.0 in 2025, then slumped by 183.24% to 35811000.0 in 2026.
- Business Quant data shows MGNX's Cash from Operations at 35811000.0 in Q1 2026, 43021000.0 in Q4 2025, and 30186000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | -40.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.75 Mn |
| Mar 31, 2026 | -35.81 Mn |
| Dec 31, 2025 | 43.02 Mn |
| Sep 30, 2025 | -30.19 Mn |
| Jun 30, 2025 | -46.99 Mn |
| Mar 31, 2025 | -46.89 Mn |
| Dec 31, 2024 | -38.41 Mn |
| Sep 30, 2024 | 60.16 Mn |
| Jun 30, 2024 | -44.49 Mn |
| Mar 31, 2024 | -45.64 Mn |
| Dec 31, 2023 | -28.04 Mn |
| Sep 30, 2023 | -35.25 Mn |
| Jun 30, 2023 | -2.09 Mn |
| Mar 31, 2023 | -12.83 Mn |
| Dec 31, 2022 | 29.32 Mn |
| Sep 30, 2022 | -9.42 Mn |
| Jun 30, 2022 | -49.16 Mn |
| Mar 31, 2022 | -57.70 Mn |
| Dec 31, 2021 | -54.31 Mn |
| Sep 30, 2021 | -14.80 Mn |